<p>Cerebrovascular adverse reactions in elderly patients with dementia-related psychosis: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack).<br />
<br />
<strong>Neuroleptic malignant syndrome</strong>: Manage with immediate discontinuation and close monitoring.<br />
<br />
<strong>Tardive dyskinesia</strong>: Discontinue if clinically appropriate.<br />
<br />
<strong>Metabolic changes</strong>: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain.<br />
<br />
<strong>Hyperglycemia and diabetes mellitus</strong>: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes.<br />
<br />
<strong>Dyslipidemia</strong>: Undesirable alterations have been observed in patients treated with atypical antipsychotics.<br />
<br />
<strong>Weight Gain</strong>: Gain in body weight has been observed. Monitor weight.<br />
<br />
<strong>Hyperprolactinemia</strong>: Prolactin elevations may occur.<br />
<br />
<strong>Leukopenia, neutropenia and agranulocytosis</strong>:&nbsp;Perform complete blood counts (CBC) in patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia or neutropenia. Consider discontinuing Lurasidone if a clinically significant decline in WBC occurs in the absence of other causative factors.<br />
<br />
<strong>Orthostatic hypotension and syncope</strong>: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment. In patients with known cardiovascularor cerebrovascular disease, and in antipsychotic-na&iuml;ve patients, consider a lower starting dose and slower titration.</p>